60189-34-6

60189-34-6 structure

Name: Cosyntropin (acetate)
Chemical Name: (5S,8S,11S,14S,17S)-17-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-Amino-1,3-dihydroxypropylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxypropylidene]amino}-1-hydroxy-4-(methylsulfanyl)butylidene]amino}-1-{[(2S)-6-amino-1-{(2S)-2-[hydroxy(imino)methyl]-1-pyrrolidinyl}-1-oxo-2-hexanyl]imino}-11-benzyl-8-(3-carbamimidamidopropyl)-1,4,7,10,13,16-hexahydroxy-14-(1H-imidazol-5-ylmethyl)-5-(1H-indol-3-ylmethyl)-3,6,9,12,15-pentaazaicosa-3,6,9,12,15-pentaen-20-oic acid acetate (1:1)
CAS Number: 60189-34-6
Molecular Formula: C₇₂H₁₀₂N₂₀O₁₉S
Molecular Weight: 1583.768
Catalog: Research Areas Endocrinology
Create Date: 2018-07-17 06:36:47
Modify Date: 2025-08-25 16:15:24
Tetracosactide acetate is a synthetic peptide stimulating the release of corticosteroids such as cortisol from the adrenal gland. Tetracosactide acetate is currently used for the research of ulcerative colitis and Crohn's disease, juvenile/adult rheumatoid arthritis and osteoarthrosis[1].

Name	(5S,8S,11S,14S,17S)-17-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-Amino-1,3-dihydroxypropylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxypropylidene]amino}-1-hydroxy-4-(methylsulfanyl)butylidene]amino}-1-{[(2S)-6-amino-1-{(2S)-2-[hydroxy(imino)methyl]-1-pyrrolidinyl}-1-oxo-2-hexanyl]imino}-11-benzyl-8-(3-carbamimidamidopropyl)-1,4,7,10,13,16-hexahydroxy-14-(1H-imidazol-5-ylmethyl)-5-(1H-indol-3-ylmethyl)-3,6,9,12,15-pentaazaicosa-3,6,9,12,15-pentaen-20-oic acid acetate (1:1)

Description	Tetracosactide acetate is a synthetic peptide stimulating the release of corticosteroids such as cortisol from the adrenal gland. Tetracosactide acetate is currently used for the research of ulcerative colitis and Crohn's disease, juvenile/adult rheumatoid arthritis and osteoarthrosis[1].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> Others >> Others
References	[1]. Francesco Iuliano, et al. Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation.